EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma
EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma
复制标题
DOI：
10.1093/jjco/hyq248
复制
发表时间：
2011-04-01
影响因子：
2.4
通讯作者：
Heo, Dae Seog
中科院分区：
文献类型：
--
作者：
Koh, Youngil;Jang, Bogun;Heo, Dae Seog
目的：本研究的目的是明确表皮生长因子受体（EGFR）基因拷贝数增加对术后接受辅助化疗的肺腺癌患者的预后影响。方法：该研究纳入了 95 名接受非小细胞肺癌根治性切除的腺癌患者。患者接受由紫杉醇和卡铂组成的辅助化疗。我们对组织芯片进行双份荧光原位杂交检测EGFR拷贝数变化。结果：93例患者获得EGFR荧光原位杂交结果，阳性率为32.6%。 EGFR 拷贝数变化与年龄、性别或吸烟史无关。然而，EGFR 拷贝数增加与诊断时高肿瘤标准化摄取值相关（P = 0.042）。就无病生存期（未达到中位无病生存期与 23.6 个月，P = 0.037）和总生存期（中位总生存期为 74.6 与 43.5 个月，P = 0.032）而言，EGFR 拷贝数的增加是负面预后因素。多变量分析中，EGFR 拷贝数的增加与无病生存期短独立相关（风险比 2.039，P = 0.025）。 结论：EGFR 拷贝数增加与侵袭性肿瘤生物学相关，并且是接受紫杉醇和卡铂辅助化疗的已切除肺腺癌患者肿瘤复发的不良预后因素。
Objective: The purpose of our study was to define the prognostic impact of increased copies of epidermal growth factor receptor (EGFR) gene in lung adenocarcinoma patients receiving adjuvant chemotherapy after surgery.Methods: The study included 95 adenocarcinoma patients who received curative resection for non-small cell lung cancer. Patients received adjuvant chemotherapy composed of paclitaxel and carboplatin. We performed fluorescent in situ hybridization on tissue microarray in duplicate to detect EGFR copy number change.Results: The EGFR fluorescent in situ hybridization result was available in 93 patients with a positive rate of 32.6%. EGFR copy number change did not correlate with age, gender or smoking history. However, EGFR copy number gain was related to high tumor standardized uptake value at diagnosis (P = 0.042). An increase in EGFR copy number was a negative prognostic factor in terms of disease-free survival (median disease-free survival not reached versus 23.6 months, P = 0.037) and overall survival (median overall survival 74.6 versus 43.5 months, P = 0.032). An increase in EGFR copy number was independently related to short disease-free survival in multivariate analysis (hazard ratio 2.039, P = 0.025).Conclusions: EGFR copy number gain is associated with aggressive tumor biology and is a poor prognostic factor for tumor relapse in resected lung adenocarcinoma patients receiving adjuvant chemotherapy of paclitaxel and carboplatin.